Additionally, TGF-β has been shown to modulate the release of pain-related molecules, including nerve growth factor (NGF) and other neurotrophic factors, which can sensitize nociceptive pathways and contribute to the development of hyperalgesia in cancer patients [176, 177]. This evidence concerns the gene TGFB1 and cancer.